{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:16:46Z","timestamp":1777508206376,"version":"3.51.4"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            SS750 [(\n            <jats:italic>R<\/jats:italic>\n            )-(\u2212)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1\n            <jats:italic>H<\/jats:italic>\n            -1,2,4-triazol-1-yl)-2-propanol] is a new triazole, and its potential as an antifungal agent was evaluated by in vitro and in vivo studies. In a comparison of the MICs at which 50% of isolates are inhibited (MIC\n            <jats:sub>50<\/jats:sub>\n            s) for all strains of\n            <jats:italic>Candida<\/jats:italic>\n            species and\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            tested, SS750 was four times or more active than fluconazole and had activity comparable to that of itraconazole. The most important advantage of SS750 was that, when the MIC\n            <jats:sub>90<\/jats:sub>\n            s were compared, SS750 had 64 and 32 times greater antifungal activities than fluconazole against\n            <jats:italic>Candida krusei<\/jats:italic>\n            and\n            <jats:italic>Candida glabrata<\/jats:italic>\n            , respectively, which are intrinsically less susceptible to fluconazole. In cyclophosphamide-immunosuppressed mouse models of systemic and pulmonary candidiasis caused by\n            <jats:italic>C. albicans<\/jats:italic>\n            , oral SS750 prolonged the number of days of survival of infected animals in a dose-dependent manner and was 4 and \u226564 times more potent than fluconazole and itraconazole, respectively. In a safety profile, SS750, like fluconazole, had less of an affinity for binding to mammalian cytochrome P450 compared with that of ketoconazole, despite its strong affinity for binding to fungal cytochrome P450. The mechanism for the increased in vitro antifungal activity of SS750 against\n            <jats:italic>C. krusei<\/jats:italic>\n            is partially due to the potent inhibitory activity (3.7 times versus that of fluconazole) of\n            <jats:italic>C. krusei<\/jats:italic>\n            cytochrome P450 sterol 14\u03b1-demethylase; SS750 showed a strong affinity for binding to cytochrome P450 of\n            <jats:italic>C. krusei<\/jats:italic>\n            , indicating that SS750 acts by inhibiting the cytochrome P450 sterol 14\u03b1-demethylase of fungal cells.\n          <\/jats:p>","DOI":"10.1128\/aac.46.2.308-314.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Strong Antifungal Activity of SS750, a New Triazole Derivative, Is Based on Its Selective Binding Affinity to Cytochrome P450 of Fungi"],"prefix":"10.1128","volume":"46","author":[{"given":"Masaru","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Central Research Laboratories, SSP Co., Ltd., Narita, Chiba 286-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ishida","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, SSP Co., Ltd., Narita, Chiba 286-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Konagai","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, SSP Co., Ltd., Narita, Chiba 286-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Maebashi","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, SSP Co., Ltd., Narita, Chiba 286-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takemitsu","family":"Asaoka","sequence":"additional","affiliation":[{"name":"Central Research Laboratories, SSP Co., Ltd., Narita, Chiba 286-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/02681218680000221","volume":"24","year":"1986","unstructured":"Barrett-Bee, K. J., A. C. Lane, and R. W. Turner. 1986. The mode of antifungal action of tolnaftate. J. Med. Vet. Mycol.24:155\u2013160.","journal-title":"J. Med. Vet. Mycol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.49.173","volume":"49","year":"2001","unstructured":"Eto, H., Y. Kaneko, S. Takeda, M. Tokizawa, S. Sato, K. Yoshida, S. Namiki, M. Ogawa, K. Maebashi, K. Ishida, M. Matsumoto, and T. Asaoka. 2001. New antifungal 1,2,4-triazoles with difluoro (substituted sulfonyl) methyl moiety. Chem. Pharm. Bull.49:173\u2013182.","journal-title":"Chem. Pharm. Bull."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.499"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.1.2.187"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/bj2600549","volume":"260","year":"1989","unstructured":"Hitchcock, C. A., S. B. Brown, E. G. V. Evans, and D. J. Adams. 1989. Cytochrome P-450-dependent 14\u03b1-demethylation of lanosterol in Candida albicans. Biochem. J.260:549\u2013556.","journal-title":"Biochem. J."},{"key":"e_1_3_2_7_2","unstructured":"Guidelines for animal experimentation 1987"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003495-199753040-00001","volume":"53","year":"1997","unstructured":"Kauffman, C. A., and P. L. Carver. 1997. Antifungal agents in the 1990s. Drugs53:539\u2013549.","journal-title":"Drugs"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.2.277"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.3.477"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1439-0507.1995.tb00032.x","volume":"38","year":"1995","unstructured":"Marichal, P., J. Gorrens, M.-C. Coene, L. L. Jeune, and H. Vanden Bossche. 1995. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses38:111\u2013117.","journal-title":"Mycoses"},{"key":"e_1_3_2_13_2","first-page":"253","volume":"117","year":"1980","unstructured":"Mariott, M. S. 1980. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J. Gen. Microbiol.117:253\u2013255.","journal-title":"J. Gen. Microbiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3314\/jjmm.35.263","volume":"35","year":"1994","unstructured":"Mikami, Y., T. Sakamoto, K. Yazawa, Y. Tanaka, and A. Matsumae. 1994. Effect of carrier solvents on the efficacy of oral itraconazole therapy in aspergillosis in mice. Jpn. J. Med. Mycol.35:263\u2013267.","journal-title":"Jpn. J. Med. Mycol."},{"key":"e_1_3_2_15_2","unstructured":"Reference method for broth dilution antifungal susceptibility testing for yeasts 1997"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)82244-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2645"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.1.86"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-199207050-00003","volume":"7","year":"1992","unstructured":"Perfect, J. R., M. H. Lindsay, and R. H. Drew. 1992. Adverse drug reactions to systemic antifungals: prevention and management. Drug Safety7:323\u2013363.","journal-title":"Drug Safety"},{"key":"e_1_3_2_20_2","first-page":"163","volume":"51","year":"1996","unstructured":"Poirier, J. M., F. Berlioz, F. Isnard, and G. Cheymol. 1996. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie51:163\u2013167.","journal-title":"Therapie"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00002018-199005020-00003","volume":"5","year":"1990","unstructured":"Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Safety5:94\u2013108.","journal-title":"Drug Safety"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ps.2780210406","volume":"21","year":"1987","unstructured":"Vanden Bossche, H., P. Marichal, J. Gorrens, D. Bellens, H. Verhoeven, M.-C. Coene, W. Lauwers, and P. A. J. Janssen. 1987. Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pestic. Sci.21:289\u2013306.","journal-title":"Pestic. Sci."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1382"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.900"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.308-314.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.2.308-314.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:31:05Z","timestamp":1645464665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.2.308-314.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1128\/AAC.46.2.308-314.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.2.308-314.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"2001-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}